Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al

Ann Rheum Dis. 2021 Mar;80(3):e38. doi: 10.1136/annrheumdis-2020-217955. Epub 2020 Jun 5.

Philippe Guilpain^{1

2}, Clément Le Bihan³, Vincent Foulongne⁴, Patrice Taourel⁵, Nathalie Pansu³, Alexandre Thibault Jacques Maria^{6

2}, Boris Jung^{7

8}, Romaric Larcher^{7

8}, Kada Klouche^{7

8}, Vincent Le Moing³

¹ Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, Universite Montpellier, Medical School, Montpellier Cedex 5, France.
² IRMB, Universite Montpellier, INSERM, Montpellier, France.
³ Tropical and Infectious Diseases, Hôpital Saint Eloi, CHRU de Montpellier, Montpellier Cedex 5, Hérault, France.
⁴ Pathogenesis and Control of Chronic Infections, Inserm, Universite Montpellier 1 Faculte de Medecine Montpellier-Nimes, Montpellier, Languedoc-Roussillon, France.
⁵ Osteoarticular Medical Imaging Section, Department of Medical Imaging, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France.
⁶ Internal Medicine: Multi-Organic Diseases, Local Referral Center for Systemic Autoimmune Diseases, Montpellier University Hospital, Universite Montpellier, Medical School, Montpellier Cedex 5, France alexandremaria@hotmail.fr.
⁷ Department of Intensive Care Medicine, Lapeyronie University Hospital, and PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.
⁸ Lapeyronie University Hospital, and PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.

No abstract available

Keywords: B-Lymphocytes; autoantibodies; rituximab.

Publication types